Who
Gregory Norden
Director
Company insider
Files Form 4 as: Director, Praxis Precision Medicines; Director, Royalty Pharma; Director, Zoetis; Director, NanoString Technologies; Director, Entasis Therapeutics Holdings; Director, K-V Pharmaceutical Co; Director, Human Genome Sciences; Sr. VP and CFO, Wyeth.
In numbers
- Trades disclosed
- 156
- Buys
- 3
- Sells
- 5
- Bought
- $269K
- Sold
- $3.5M
- Companies
- 8
- Companies where not an officer
- 7
- First trade
- 29 Feb 2008
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision MedicinesBiotechnology | SEC FORM 4 Code A | —1,371 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —648 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —648 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision MedicinesBiotechnology | SEC FORM 4 Code A | —1,371 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —4,545 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —4,545 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $161K3,045 at $53.00 | filing |
| 14 May 2026filed 15 May 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $161K3,045 at $53.00 | filing |
| 9 Mar 2026filed 10 Mar 2026 | ZTS ZoetisPharmaceuticals | SEC FORM 4 Code G | —1,213 at $0.00 | filing |
| 9 Mar 2026filed 10 Mar 2026 | ZTS ZoetisPharmaceuticals | SEC FORM 4 Code G | —1,213 at $0.00 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ZTS ZoetisPharmaceuticals | SEC FORM 4 Code M | —1,619 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ZTS ZoetisPharmaceuticals | SEC FORM 4 Code J | $52K406 at $127.28 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,619.333 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,619.33 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ZTS ZoetisPharmaceuticals | SEC FORM 4 Code M | —1,619 | filing |
| 19 Feb 2026filed 23 Feb 2026 | ZTS ZoetisPharmaceuticals | SEC FORM 4 Code J | $52K406 at $127.28 | filing |
| 18 Feb 2026filed 19 Feb 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,936 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | ZTS Zoetisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,936 at $0.00 | filing |
| 11 Aug 2025filed 11 Aug 2025 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Sold | $1.2M33,500 at $36.23 | filing |
| 8 Aug 2025filed 11 Aug 2025 | RPRX Royalty Pharmaoption or derivative · Pharmaceuticals | SEC FORM 4 Code C | —14,466 at $0.00 | filing |
News
Royalty Pharma (NASDAQ:RPRX) and Aditxt (NASDAQ:ADTX) Financial ComparisonRPRX · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Gregory Norden; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.